Last reviewed · How we verify
NCT06339021
OCT or Angiography Guided De-escalation of DAPT
EARLY_PHASE1 trial testing OCT-guided PCI in Optical Coherence Tomography in 80 participants. Not yet recruiting.
1 December 2026
Quick facts
| Lead sponsor | Shenyang Northern Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 April 2024 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- OCT-guided PCI
- Conventional angiography-based PCI
- DAPT de-escalation — full drug profile →
- default DAPT regimen — full drug profile →
Conditions studied
- Optical Coherence Tomography — all drugs for Optical Coherence Tomography →
- Dual Antiplatelet Therapy — all drugs for Dual Antiplatelet Therapy →
- Antiplatelet De-escalation — all drugs for Antiplatelet De-escalation →
- Neointimal Coverage — all drugs for Neointimal Coverage →
Sponsor
Shenyang Northern Hospital
Who can join
Adults 18 to 75, any sex, with Optical Coherence Tomography or Dual Antiplatelet Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events. Based on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06339021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of OCT-guided PCI
Trials testing the same drug.
- NCT06154395 — Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction · NA · recruiting
- NCT05493904 — PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX) · NA · active not recruiting
- NCT03625908 — Optical CoherenCe Tomography-gUided Coronary Intervention in Patients With Complex lesIons: a Randomized Controlled Tria · NA · completed
- NCT04444037 — Impact of OCT Imaging on Decision Making During PCI in ACS Patients · completed
Other recruiting trials for Optical Coherence Tomography
Currently open trials in the same condition.
- NCT06040073 — Natural History of Coronary Atherosclerosis · recruiting
- NCT06520904 — Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography · Phase 4 · recruiting
- NCT06436482 — Research of Endobronchial Optical Coherence Tomography in Pre-COPD · recruiting
- NCT05340361 — Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT · recruiting
- NCT05230446 — PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlus · NA · recruiting
Other Shenyang Northern Hospital trials
Trials by the same sponsor.
- NCT07445360 — Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary V · NA · not yet recruiting
- NCT07374718 — Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate- · NA · not yet recruiting
- NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
- NCT07362966 — Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant · Phase 4 · not yet recruiting
- NCT07383155 — Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06339021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenyang Northern Hospital
- Last refreshed: 1 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06339021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing